Combination of Lanreotide Autogel 120mg and Temozolomide in Progressive GEP-NET
Status:
Completed
Trial end date:
2017-06-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to evaluate the efficacy and tolerability of the combination of
Lanreotide Autogel 120 mg and Temozolomide in patients with progressive
gastro-entero-pancreatic neuroendocrine tumours (GEP-NET) graded as G1 or G2 (G1/G2). All
progressive tumours classified according to Response Evaluation Criteria In Solid Tumours
(RECIST, 1.1).